Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency
Status: open17-247 - A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency
Treatment for Heart Failure with Iron deficiency
Description
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with iron deficiency and with a reduced ejection fraction.
Sponsors
This trial is sponsored by Luitpold Pharmaceuticals.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at 251-471-7027 or by email at crevere@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
Sub Investigators
![Bassam Omar]()
View ProfileBassam A. Omar, M.D., Ph.D., F.A.C.C.CardiologistFellowship Director of Cardiovascular Diseases; Professor of Internal Medicine![Ghulam Mustafa Awan]()
View ProfileGhulam Mustafa Awan, M.D.Interventional CardiologistDirector of Interventional Cardiology and Endovascular Interventions; Associate Professor of Internal Medicine
